Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Items 101–200 of 486
Emmenegger, M., Cecco, E. D., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D. V., Schneider, M. M., Morales, I. C., et al. (2023) · iScience · doi:10.1101/2020.05.31.20118554 · Cited by 34
Leal, F. E., Mendes-Corrêa, M. C., Buss, L., Costa, S. F., Bizário, J. C. S., de Souza, S. R. P., Thomaz, O., Tozetto‐Mendoza, T. R., Villas-Boas, L. S., Silva, L. C. D. O.-D., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042745 · Cited by 42
Self-citationKemp, F., Proverbio, D., Aalto, A., Mombaerts, L., d’Hérouël, A. F., Husch, A., Ley, C., Gonçalves, J. M., Skupin, A., & Magni, S. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110874 · Cited by 49
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 43
“Brazil was expected to have surpassed the theoretical herd immunity threshold (67%) [198].”
Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study
Mercado, M., Malagón-Rojas, J., Rodríguez-Barraquer, I., Zapata-Bedoya, S., Wiesner, M., Cucunubá, Z. M., Toloza-Pérez, Y. G., Hernandez-Ortiz, J. P., Acosta-Reyes, J. L., Parra-Barrera, E. L., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100195 · Cited by 37
Sansone, N. M. S., Boschiero, M. N., & Marson, F. A. L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.911036 · Cited by 39
Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy
Giallonardo, F. D., Puglia, I., Curini, V., Cammà, C., Mangone, I., Calistri, P., Cobbin, J. C. A., Holmes, E. C., & Lorusso, A. (2021) · Viruses · doi:10.3390/v13050794 · Cited by 39
“This variant was first reported in Manaus (Brazil), which was hit hard by the first wave of SARS-CoV-2 with an estimated 76% of the population infected [27].”
BackgroundTMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction
Khan, H., Winstone, H., Jiménez-Guardeño, J. M., Graham, C., Doores, K. J., Goujon, C., Matthews, D. A., Davidson, A. D., Rihn, S. J., Palmarini, M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009820 · Cited by 35
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · PubMed · doi:10.34944/dspace/7022 · Cited by 49
What the reproductive number R0 can and cannot tell us about COVID-19 dynamics
Shaw, C. L., & Kennedy, D. A. (2021) · Theoretical Population Biology · doi:10.1016/j.tpb.2020.12.003 · Cited by 43
Schoenhals, M. J., Rabenindrina, N., Rakotondramanga, J. M., Dussart, P., Randremanana, R. V., Héraud, J., Andriamandimby, S. F., Sahondranirina, P. H., Vololoniaina, M. C., Randriatsarafara, F. M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103419 · Cited by 34
“High seroprevalences and attack rates as high as 75% were described after the first epidemic peak [22], but this city was devastated by a second peak in December.”
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 38
“The emergence of this variant was associated with a resurgence of COVID-19 in Manaus, Brazil, resulting in an abrupt increase in the number of cases and deaths in this part of the world in January 2021 (22, 24, 28, 126).”
BackgroundReinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
Junior, C. A. P., Buss, L., Buccheri, R., Abrahim, C. M. M., Salomon, T., Crispim, M. A. E., Oikawa, M. K., Grebe, E., Costa, A. G., Fraiji, N. A., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07094-y · Cited by 43
“Introduction Approximately 76% of the inhabitants of Manaus had been infected with SARS-CoV-2 eight months after the first reported case in March 2020 [1].”
BackgroundSelf-citationCOVID-19 in Latin America: A Snapshot in Time and the Road Ahead
LaRotta, J., Escobar, O., Avila-Aguero, M. L., Torres, J. P., de Almeida, R. S., Morales, G. D. C., & Srivastava, A. K. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00748-z · Cited by 49
“For example, in Manaus, Brazil, despite an estimated 76% attack rate in October 2020, a sharp increase in infections and hospitalizations was observed in January 2021; while likely attributed, in part, to waning immunity, these increases were also probably potentiated by poor infection control measures [40, 60].”
BackgroundWithin-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
Moelling, K. (2021) · Viruses · doi:10.3390/v13050751 · Cited by 34
“This was estimated as above the theoretical threshold for herd immunity (60–67%) [23,24].”
BackgroundInfluentialImmune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
Paniskaki, K., Anft, M., Meister, T. L., Marheinecke, C. S., Pfaender, S., Skrzypczyk, S., Seibert, F. S., Thieme, C. J., Konik, M., Dolff, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816220 · Cited by 34
“A year since the first anti-SARS-CoV-2 vaccine was approved for use (1, 2), increasing concerns have arisen regarding the effectiveness of the existing SARS-CoV-2 vaccines against variants of concern (VOCs).”
BackgroundCOVID-19: Epidemiologie und Mutationen
Hemmer, C. J., Löbermann, M., & Reisinger, E. C. (2021) · Der Radiologe · doi:10.1007/s00117-021-00909-0 · Cited by 71
IMPACT OF PUBLIC HEALTH AWARENESS PROGRAMS ON COVID-19 DYNAMICS: A FRACTIONAL MODELING APPROACH
Zafar, Z. U. A., Yusuf, A., Musa, S. S., Qureshi, S., Alshomrani, A. S., & Bǎleanu, D. (2022) · Fractals · doi:10.1142/s0218348x23400054 · Cited by 33
Rodrigues, E. P. S., Abreu, I. N., Lima, C. N. C., Fonseca, D. L. M., Pereira, S. F. G., dos Reis, L. C., Vallinoto, I. M. V. C., Guerreiro, J. F., & Vallinoto, A. C. R. (2021) · International Journal for Equity in Health · doi:10.1186/s12939-021-01392-8 · Cited by 33
“The high prevalence observed in the Xikrin village was also reported in Manaus, the capital of Amazonas state, where 76 % of the population had detectable IgG antibodies in October [10].”
BackgroundBrain cross‐protection against SARS‐CoV‐2 variants by a lentiviral vaccine in new transgenic mice
Ku, M., Authié, P., Bourgine, M., Anna, F., Noirat, A., Moncoq, F., Vesin, B., Névo, F., Lopez, J., Souque, P., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114459 · Cited by 33
“Mice were then challenged at week 7 with the SARS-CoV-2 Gamma strain which is among the most genetically distant SARS-CoV-2 variants so far described (Buss et al, 2021).”
MethodGräf, T., Bello, G., Venas, T. M. M., Pereira, E. C., Paixão, A. C. D., Appolinario, L., Lopes, R. S., Mendonça, A. C. D. F., da Rocha, A. S. B., Motta, F. C., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab091 · Cited by 41
Self-citationCo-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021
Stefanelli, P., Trentini, F., Dirani, G., Marziano, V., Mammone, A., Poletti, P., Grané, C. M., Manica, M., Manso, M. D., Andrianou, X. D., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.5.2100429 · Cited by 34
SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo
Nakayama, E. E., & Shioda, T. (2023) · Microorganisms · doi:10.3390/microorganisms11041015 · Cited by 34
The COVID-19 Vaccination Strategy in Brazil—A Case Study
Bernardeau-Serra, L., Nguyen-Huynh, A., Sponagel, L., Guimarães, N. S., de Aguiar, R. A. T., & Marcolino, M. S. (2021) · Epidemiologia · doi:10.3390/epidemiologia2030026 · Cited by 39
A spatio-temporal model based on discrete latent variables for the analysis of COVID-19 incidence
Bartolucci, F., & Farcomeni, A. (2021) · Spatial Statistics · doi:10.1016/j.spasta.2021.100504 · Cited by 37
“Simultaneously, pathogenicity is high enough to generate a proportion of severe cases (Buss et al., 2021; Del Sole et al., 2020) that can overwhelm health systems (Grasselli et al., 2020; Farcomeni et al., 2021a) when prevalence is high.”
Learning from the past: Taiwan’s responses to COVID-19 versus SARS
Yen, M., Yen, Y., Chen, S., Lee, T.-I., Huang, K.-H., Chan, T., Tung, T.-H., Hsu, L., Chiu, T., Hsueh, P., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.002 · Cited by 34
Chen, S., Flegg, J. A., White, L. J., & Aguas, R. J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009436 · Cited by 29
“Whereas one study reports a raw seroprevalence of approximately 40% [37] using the Abbot test, the other reports an antibody positivity of approximately 13% [38] using the WONDFO SARS-CoV-2 antibody test, with both measured in May 2020.”
MethodGoldfarb, D. A., Mâsse, L. C., Watts, A. W., Hutchison, S. M., Muttucomaroe, L., Bosman, E. S., Barakauskas, V., Choi, A., Dhillon, N., Irvine, M. A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057846 · Cited by 27
Lucinde, R. K., Mugo, D., Bottomley, C., Karani, A., Gardiner, E., Aziza, R., Gitonga, J. N., Karanja, H., Nyagwange, J., Tuju, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265478 · Cited by 35
“As discussed, we lack local data on the rate of antibody waning, which is important to estimate cumulative incidence of infection from snapshot seroprevalence estimates [37,38].”
BackgroundEstofolete, C. F., Banho, C. Á., Campos, G. R. F., Marques, B. D. C., Sacchetto, L., Ullmann, L. S., Possebon, F. S., Machado, L. F., Syrio, J. D., Araújo, J. P., et al. (2021) · Viruses · doi:10.3390/v13071237 · Cited by 30
“Data showed that up to three-quarters of its population had been infected by SARS-CoV-2 in the first months of 2020, leading epidemiologists to suggest that herd immunity may have contained the epidemic [18,19].”
BackgroundIbarra-Espinosa, S. A., de Freitas, E. D., Ropkins, K., Dominici, F., & Rehbein, A. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112369 · Cited by 35
Yakusheva, O., van den Broek‐Altenburg, E. M., Brekke, G., & Atherly, A. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261759 · Cited by 28
Bharathi, M., Sivamaruthi, B. S., Kesika, P., Thangaleela, S., & Chaiyasut, C. (2022) · Marine Drugs · doi:10.3390/md20020148 · Cited by 28
Infection fatality rate and infection attack rate of COVID-19 in South American countries
Musa, S. S., Tariq, A., Liu, Y., Wei, H., & He, D. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00961-5 · Cited by 31
“0 during the hugely unmitigated outbreak [10, 11], which indicates high transmission potential of the virus to spread and cause large outbreaks.”
BackgroundInfluentialMartins, T. C. D. F., & Guimarães, R. M. (2022) · Saúde em Debate · doi:10.1590/0103-11042022e118 · Cited by 36
Goldenbogen, B., Adler, S. O., Bodeit, O., Wodke, J. A. H., Escalera‐Fanjul, X., Korman, A., Krantz, M., Bonn, L., Morán‐Torres, R., Haffner, J., et al. (2022) · Advanced Science · doi:10.1002/advs.202200088 · Cited by 27
Gaskell, K. M., Johnson, M., Gould, V., Hunt, A., Stone, N. R. H., Waites, W., Kasstan, B., Chantler, T., Lal, S. D., Roberts, C. H., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100127 · Cited by 25
“However over the course of 2020, the overall seroprevalence in this tightly knit religious community reached levels similar to those seen in Manaus, Brazil where a seroprevalence of more than 65% has been reported in adults [21].”
BackgroundUsing Proper Mean Generation Intervals in Modeling of COVID-19
Tang, X., Musa, S. S., Zhao, S., Mei, S., & He, D. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.691262 · Cited by 25
Franceschi, V. B., Ferrareze, P. A. G., Zimerman, R. A., Cybis, G. B., & Thompson, C. E. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198532 · Cited by 30
Smith, M. R., Trofimova, M., Weber, A., Duport, Y., Kühnert, D., & von Kleist, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26267-y · Cited by 30
Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
Bottomley, C., Otiende, M., Uyoga, S. M., Gallagher, K. E., Kagucia, E. W., Etyang, A. O., Mugo, D., Gitonga, J. N., Karanja, H., Nyagwange, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26452-z · Cited by 31
Rapid Identification of SARS-CoV-2 Variants of Concern Using a Portable peak PCR Platform
Bechtold, P., Wagner, P., Hosch, S., Siegrist, D., Ruiz‐Serrano, A., Gregorini, M., Mpina, M., Ndoho, F. A. O., Obama, J., Ayekaba, M. O., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02368 · Cited by 27
The challenge of emerging SARS-CoV-2 mutants to vaccine development
Li, R., Liu, J., & Zhang, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.001 · Cited by 25
Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 25
Impact of exposure to smoke from biomass burning in the Amazon rain forest on human health
Urrutia‐Pereira, M., Rizzo, L. V., Chong‐Neto, H. J., & Solé, D. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210219 · Cited by 60
Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020–2021
Nicolete, V. C., Rodrigues, P. T., Fernandes, A. R. J., Corder, R. M., Tonini, J., Buss, L., Sales, F. C. D. S., Faria, N. R., Sabino, É. C., Castro, M. C., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2803.211993 · Cited by 32
Self-citationGrebe, E., Stone, M., Spencer, B. R., Akinseye, A., Wright, D. J., Germanio, C. D., Bruhn, R. L., Zurita, K. G., Contestable, P., Green, V., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3008.240659 · Cited by 24
“Nucleocapsid IgG assays used in numerous serosurveillance studies ( 14 , 24 – 28 ) show more rapid waning in antibody signal than nucleocapsid total Ig assays ( 13 ) and thus require adjustments for seroreversion in estimating cumulative incidence ( 14 ).”
Self-citationThe unexpected dynamics of COVID-19 in Manaus, Brazil: Was herd immunity achieved?Preprint
He, D., Artzy‐Randrup, Y. A., Musa, S. S., Gräf, T., Naveca, F. G., & Stone, L. (2021) · medRxiv · doi:10.1101/2021.02.18.21251809 · Cited by 24
Di, A., Cunha, F., Petrosillo, N., Beeching, N. J., Ergonul, O., Petersen, E., & Koopmans, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.011 · Cited by 26
“A study from Brazil found that 76% of the population had been infected with SARS-CoV-2 by October 2020 [31].”
Perkmann, T., Mucher, P., Perkmann‐Nagele, N., Radakovics, A., Repl, M., Köller, T., Schmetterer, K. G., Bigenzahn, J. W., Leitner, F., Jordakieva, G., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01402-21 · Cited by 23
He, D., Lin, L., Artzy‐Randrup, Y., Demirhan, H., Cowling, B. J., & Stone, L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211422120 · Cited by 28
“The simulated model (black line; for 𝜓 = 0 ) fits the Manaus mortality data well, but the attack rate of AR 1 = 38 to 40% (green line) by October 2020 is significantly lower than that of AR 1 = 76% estimated by Buss et al. (2) and 81% estimated by Faria et al. (25).”
InfluentialSingle-molecule force stability of the SARS-CoV-2–ACE2 interface in variants-of-concern
Bauer, M. S., Gruber, S., Hausch, A., Melo, M. C. R., Gomes, P. D. S. F. C., Nicolaus, T., Milles, L. F., Gaub, H. E., Bernardi, R. C., & Lipfert, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01536-7 · Cited by 24
“1), in a setting where there was already significant population immunity through natural infections 55,56 .”
COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13800 · Cited by 27
Villela, E. F. D. M., da Cunha, I. R., Fodjo, J. N. S., Obimpeh, M., Colebunders, R., & Hees, S. V. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126511 · Cited by 25
“In another study performed in Sao Paulo, south-eastern Brazil, in October 2020, the seroprevalence of SARS-CoV-2 was estimated to be 29% [16].”
BackgroundDynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave
Ferrante, L., Duczmal, L. H., Capanema, E., Steinmetz, W. A. C., Almeida, A. C. L., Leão, J., Vassão, R. C., Fearnside, P. M., & Tupinambás, U. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101752 · Cited by 31
A framework for reconstructing SARS-CoV-2 transmission dynamics using excess mortality data
Ghafari, M., Watson, O. J., Karlinsky, A., Ferretti, L., & Katzourakis, A. (2022) · Nature Communications · doi:10.1038/s41467-022-30711-y · Cited by 22
“While the duration of antibody responses after coronavirus infection over longer timescales remains largely unknown, recent surveillance data and comparative studies have shown that re-infection with SARS-CoV-2 is possible after 3-6 months, and that older age-groups have a much lower protection against reinfection [41…”
ResultA control framework to optimize public health policies in the course of the COVID-19 pandemic
Pataro, I. M. L., de Oliveira, J. F., Morato, M. M., Amad, A. A. S., Ramos, P. I. P., Pereira, F. A., Silva, M. S., Jorge, D. C. P., Andrade, R. F. S., Barreto, M. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92636-8 · Cited by 35
A data-driven model for COVID-19 pandemic – Evolution of the attack rate and prognosis for Brazil
Filho, T. M. R., Moret, M. A., Chow, C. C., Phillips, J. C., Cordeiro, A., Scorza, F. A., de Almeida, A.-C. G., & Mendes, J. F. F. (2021) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2021.111359 · Cited by 23
Chandrashekar, A., Liu, J., Yu, J., McMahan, K., Tostanoski, L. H., Jacob-Dolan, C., Mercado, N. B., Anioke, T., Chang, A., Gardner, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2641 · Cited by 23
Ferrante, L., Duczmal, L. H., Steinmetz, W. A. C., Almeida, A. C. L., Leão, J., Vassão, R. C., Tupinambás, U., & Fearnside, P. M. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01148-8 · Cited by 27
COVID-19 vaccination strategies depend on the underlying network of social interactions
Saunders, H., & Schwartz, J.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03167-1 · Cited by 20
“We assessed changes in these parameters against the following four outputs: (1) the maximum percentage of a population that is infected at one time, (2) the percentage of the population that is infected 2 years after the initial onset of the disease, (3) the maximum number of reinfection that occur to a single individ…”
MethodCOVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
Giau, V. V., Bagyinszky, E., & An, S. S. A. (2022) · Microorganisms · doi:10.3390/microorganisms10030598 · Cited by 21
“Manaus is a crowded region of Amazonas, and the first case of acute respiratory syndrome was observed in spring 2020 [25].”
BackgroundJunior, C. A. P., Buss, L., Salomon, T., Oikawa, M. K., Pereira, R., Moura, I., Delerino, L., Barral‐Netto, M., Tavares, N., França, R., et al. (2022) · eLife · doi:10.7554/elife.78233 · Cited by 20
“This heterogeneity in transmission in a location with high 687 overall antibody prevalence meant that some groups remained relatively susceptible and 688 perpetuated transmission at a lower level(Buss and Sabino, 2021; Lalwani et al., 2021).”
Self-citationInward, R. P. D., Parag, K. V., & Faria, N. R. (2022) · Nature Communications · doi:10.1038/s41467-022-32812-0 · Cited by 20
Self-citationChauvin, J. P. (2021) · doi:10.18235/0003458 · Cited by 20
Djaafara, B. A., Whittaker, C., Watson, O. J., Verity, R., Brazeau, N. F., WİDYASTUTİ, W., Oktavia, D., Adrian, V., Salama, N., Bhatia, S., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02016-2 · Cited by 24
Self-citationTagliamonte, M. S., Mavian, C. N., Zainabadi, K., Cash, M. N., Lednicky, J. A., Magalis, B. R., Riva, A., Deschamps, M., Liautaud, B., Rouzier, V., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab736 · Cited by 19
“Before the outbreak, a modeling study based on data from blood donors suggested that 76% of the population in Manaus had been infected with SARS-CoV-2 by October 2020, consistent with development of “herd immunity” [6].”
Uncertainty around the Long-Term Implications of COVID-19
Desforges, M., Gurdasani, D., Hamdy, A., & Leonardi, A. J. (2021) · Pathogens · doi:10.3390/pathogens10101267 · Cited by 19
“Variant P1 (now known as Gamma) spread rapidly across Manaus at a point when an estimated 76% of the population was thought to have been exposed to SARS-CoV-2 during the first wave [9].”
BackgroundAntibody Dynamics and Durability in Coronavirus Disease-19
Zuiani, A., & Wesemann, D. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.004 · Cited by 21
“Manaus had an exceptionally high rate of infection during the first phase of the pandemic in May 2020, with infection rates estimated to be 76% based on a serologic survey.(67) With this infection level, Manaus would be predicted to have achieved herd immunity.”
Daboin, B. E. G., Bezerra, Í. M. P., Morais, T. C., Portugal, I., Echeimberg, J. D. O., CESAR, A. E. M., Cavalcanti, M. P. E., Jacintho, L. C., Raimundo, R. D., Elmusharaf, K., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031153 · Cited by 24
“[6] indicate that 70% of the Manaus population had already been infected with COVID-19, which theoretically would imply herd immunity.”
BackgroundArantes, I., Bello, G., do Nascimento, V. A., de Souza, V. C., da Silva, A., Silva, D., Nascimento, F., Mejía, M., Brandão, M. J., Gonçalves, L. M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37541-6 · Cited by 22
Self-citationPossible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
Li, X., Zhang, L., Chen, S., Ouyang, H., & Ren, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071479 · Cited by 21
“Moreover, two recent reports showed that it is not a wise strategy to acquire herd immunity through natural infection [86,87].”
BackgroundL18F substrain of SARS-CoV-2 VOC-202012/01 is rapidly spreading in EnglandPreprint
Grabowski, F., Kochańczyk, M., & Tomasz Lipniacki, B. (2021) · medRxiv · doi:10.1101/2021.02.07.21251262 · Cited by 21
Ojal, J., Brand, S. P. C., Were, V. O., Okiro, E. A., Kombe, I. K., Mburu, C., Aziza, R., Ogero, M. O., Agweyu, A., Warimwe, G. M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16748.1 · Cited by 31
A snapshot of a pandemic: The interplay between social isolation and COVID-19 dynamics in Brazil
Ferreira, C. P., Marcondes, D., de Melo, M. P., Oliva, S. M., Peixoto, C., & Peixoto, P. S. (2021) · Patterns · doi:10.1016/j.patter.2021.100349 · Cited by 19
Global COVID-19 Pandemic Waves: Limited Lessons Learned Worldwide over the Past Year
Wei, Y., Guan, J., Ning, X., Li, Y., Wei, L., Shen, S., Zhang, R., Zhao, Y. C., Shen, H., & Chen, F. (2021) · Engineering · doi:10.1016/j.eng.2021.07.015 · Cited by 19
“Furthermore, Brazil once entered the first grade and contributed considerably to the global increase in cases [22].”
BackgroundFerreira, L. S., de Almeida, G. B., Borges, M. E., Simon, L. M., Poloni, S., Bagattini, Â. M., da Rosa, M. Q. M., Diniz‐Filho, J. A. F., Kuchenbecker, R. D. S., Camey, S. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.082 · Cited by 19
“These 8 values vary by each seroprevalence study, with different methodologies and study 9 sites (17,18).”
BackgroundLalwani, P. J., Araujo-Castillo, R. V., Ganoza, C. A., Salgado, B. B., Filho, I. V. P., da Silva, D. S. S., de Morais, T. B. D. N., Jordão, M. F., Ortiz, J. V., Barbosa, A. R. C., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00355-7 · Cited by 17
do Couto, A. C., Kmetiuk, L. B., Delai, R. R., Brandão, A. P. D., Monteiro, C. O., da Silva, L. H. A., Soares, C. P., Banari, A. C., Bach, R. V. W., Pettan-Brewer, C., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009754 · Cited by 19
“1% in blood donors from São Paulo observed a month later from this study (Sept 7 to 29, 2020) [19].”
BackgroundSero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitalsPreprint
Lucinde, R. K., Mugo, D., Bottomley, C., Aziza, R., Gitonga, J. N., Karanja, H., Nyagwange, J., Tuju, J., Wanjiku, P., Nzomo, E., et al. (2021) · medRxiv · doi:10.1101/2021.02.05.21250735 · Cited by 18
Páez, F. D. A., Vega, B., Orellana, D., Charry, R., Gómez, A., Obimpeh, M., Verhoeven, V., & Colebunders, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094657 · Cited by 17
“In Brazil, a SARS-CoV-2 seroprevalence of 40.4% (95% CI 35.6–45.3) was reported in Maranhão, and of 76% (95% CI 67–98) in October 2020 among blood donors in Manaus [17].”
BackgroundInfluentialAdamóski, D., de Oliveira, J. C., Bonatto, A. C., Wassem, R., Nogueira, M. B., Raboni, S. M., Trindade, E. D. S., de Souza, E. M., SCB-UFPR COVID-19 team, & Gradia, D. F. (2021) · Emerging infectious diseases · doi:10.3201/eid2712.211326 · Cited by 17
“1) emerged in the city of Manaus, Brazil, at a time when three quarters of the population had tested positive for antibodies; it proceeded to spread across the city (3).”
BackgroundFonseca, P. L. C., Moreira, F. R. R., de Souza, R. M., Guimarães, N. R., Carvalho, N. D. O., Adelino, T., Alves, H. J., Alvim, L. B., Cândido, D. D. S., Coelho, H. P., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac064 · Cited by 18
Self-citationHigh SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
Kadyrova, I., Yegorov, S., Negmetzhanov, B., Kolesnikova, Y. A., Kolesnichenko, S. I., Korshukov, I., Akhmaltdinova, L., Vazenmiller, D., Stupina, Y., Амирбековна, К. Н., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272008 · Cited by 18
Coudeville, L., Gomez, G. B., Jollivet, O., Harris, R. C., Thommes, E. W., Druelles, S., Chit, A., Chaves, S. S., & Mahé, C. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.034 · Cited by 17
Saeed, S., O’Brien, S. F., Abe, K. T., Yi, Q., Rathod, B., Wang, J., Fazel‐Zarandi, M., Tuite, A. R., Fisman, D. N., Wood, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257743 · Cited by 17
“Consistent with previous reports, we found the nucleocapsid signal from the Abbott assay also wanes faster than spike or RBD [29, 30].”
ResultSchool reopening and COVID-19 in Brazil
Barberia, L., Bastos, L. S., & de Sousa, T. M. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100149 · Cited by 16
Offerhaus, J. A., Joosten, L. P. T., van Smeden, M., Linschoten, M., Bleijendaal, H., Tieleman, R. G., Wilde, A. A. M., Rutten, F. H., Geersing, G., & Remme, C. A. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.100970 · Cited by 21
Alves, J. S., Gonçalves, A. M. D. S., Bittencourt, M. N., Alves, V. D. M., Mendes, D. T., & Nóbrega, M. D. P. S. D. S. (2022) · Revista Latino-Americana de Enfermagem · doi:10.1590/1518-8345.5768.3518 · Cited by 37
“Highlights: (1) S igni f icant results between psychopathological symptoms and work factors.”
SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors
Asghar, A., Imran, H. M., Bano, N., Maalik, S., Mushtaq, S., Hussain, A., Varjani, S., Aleya, L., Iqbal, H. M. N., & Bilal, M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22333-0 · Cited by 21
Jewell, N. P., & Lewnard, J. A. (2022) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/rssa.12860 · Cited by 14
“The validity of these conclusions that transmission could be brought under control with low population immunity has ultimately been brought into question by the persistence of severe epidemics with R > 1 even amid high population seroprevalence and aggressive vaccine rollout (Anand et al., 2021; Buss et al., 2021; Mal…”
BackgroundHigh seroprevalence of SARS_COV-2 in Bergamo: evidence for herd immunity or reason to be cautious?
Signorelli, C., Zucchi, A., Tersalvi, C. A., Ciampichini, R., Beato, E., Balzarini, F., Odone, A., & Middleton, J. (2020) · International Journal of Public Health · doi:10.1007/s00038-020-01524-x · Cited by 16
Estimating COVID-19 infection fatality rate in Mumbai during 2020Preprint
Banaji, M. (2021) · medRxiv · doi:10.1101/2021.04.08.21255101 · Cited by 16
Gupta, L., & Gaur, P. S. (2020) · Proceedings of the Shevchenko Scientific Society Medical Sciences · doi:10.25040/ntsh2020.02.05 · Cited by 15
COVID-19 herd immunity in the absence of a vaccine: an irresponsible approach
Khalife, J., & VanGennep, D. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021012 · Cited by 17
Lima, C. N. C., Abreu, I. N., Rodrigues, E. P. S., Freitas, V. D. O., Botelho, B. J. S., Souza, S. L., Vallinoto, I. M. V. C., Guerreiro, J. F., Ishak, R., & Vallinoto, A. C. R. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054271 · Cited by 15
Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood
Campbell, C., Padmanabhan, N., Romero, D., Joe, J., Gebremeskel, M., Manjula, N., Wohlstadter, N., Wohlstadter, R., Goodwin, P., Quintero, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10484-6 · Cited by 16
Hidden Perils: Diagnosing Asymptomatic Disease Carriers
Löwy, I. (2021) · Medicine Anthropology Theory · doi:10.17157/mat.8.2.5106 · Cited by 14
“…indicated that the majority of the population of Manaus, Brazil came into contact with SAS-CoV2, but the mortality from COVID-19 in this city remained high [Buss et al. 2021]); and the risk that a high level of COVID-19 circulation would enable the rise of dangerous mutations (Alwar et al. 2020).”
BackgroundAssessing the consequences of quarantines during a pandemic
Forslid, R., & Herzing, M. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01310-3 · Cited by 14
“[7] report the consequences for the Brazilian city Manaus of having let the pandemic run its course without any effective mitigation.”
Franceschi, V. B., Caldana, G. D., Perin, C., Horn, A., Peter, C., Cybis, G. B., Ferrareze, P. A. G., Rotta, L. N., Cadegiani, F., Zimerman, R. A., et al. (2021) · Pathogens · doi:10.3390/pathogens10080988 · Cited by 16
“1 sequences were grouped above the regression line, showing higher evolutionary rates than the other lineages in the SARS-CoV-2 phylogeny, as observed in other studies [11,14].”
BackgroundResult
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.